Xillix Technologies Corp. (TSX:XLX), the world leader in fluorescence endoscopy for the early detection of cancer, today announced results for the third quarter ended September 30, 2005. The Company also outlined plans for a multi-center clinical trial in colon cancer with its latest device, Onco-LIFETM, which was recently approved by the U.S. Food and Drug Administration (FDA) for use in the detection of lung cancer, the leading cause of cancer death in both men and women.
